Central Laboratory, Danyang People's Hospital of Jiangsu Province, Danyang, Jiangsu, China.
J Int Med Res. 2020 Jun;48(6):300060520932104. doi: 10.1177/0300060520932104.
Azithromycin (AZM) has been used to treat chronic inflammatory airway diseases because it regulates cell-cell contact between airway epithelial cells. Airway mucus hypersecretion is an important component of chronic respiratory diseases. Mucin 5AC (MUC5AC) is the major mucin produced by airway epithelial cells, and hypersecretion of MUC5AC is a sign of various pulmonary inflammatory diseases. Recently, it was found that matrix metallopeptidase 9 is involved in mucus hypersecretion. Moreover, AZM can inhibit the ability of TNF-α-to induce interleukin (IL)-8 production. This review focuses on the effects on AZM that may be beneficial in inhibiting MUC5AC, matrix metalloprotease-9 and IL-8 production in airway epithelial cells. In addition, recent studies have begun to assess activation of mitogen-activated protein kinase (MAPK) signaling pathways in response to AZM. Understanding these new developments may be helpful for clinicians.
阿奇霉素（AZM）已被用于治疗慢性炎症性气道疾病，因为它可调节气道上皮细胞之间的细胞-细胞接触。气道黏液高分泌是慢性呼吸道疾病的一个重要组成部分。黏蛋白 5AC（MUC5AC）是气道上皮细胞产生的主要黏蛋白，MUC5AC 的过度分泌是各种肺部炎症性疾病的一个标志。最近发现，基质金属蛋白酶 9 参与黏液高分泌。此外，AZM 可抑制 TNF-α诱导白细胞介素（IL）-8 产生的能力。本综述重点介绍 AZM 可能有益于抑制气道上皮细胞中 MUC5AC、基质金属蛋白酶-9 和 IL-8 产生的作用。此外，最近的研究开始评估 AZM 对丝裂原活化蛋白激酶（MAPK）信号通路的激活作用。了解这些新进展可能有助于临床医生。
